Related Experiment Videos
Interferon reduces hepatic drug metabolism in vivo in mice
Abstract:
The effects of two highly purified human leukocyte interferons (IFN-A and IFN-AD) on drug-metabolizing capacity in mice have been investigated. IFN-AD was found to produce significant changes in antipyrine half-life, assessed by analysis of 14CO2 exhalation rates following 14C-antipyrine administration. By contrast, IFN-A, which has considerably less antiviral potency than IFN-AD, was found to have no effect on antipyrine half-life. The administration regimen was found to markedly alter the effects seen with IFN-AD. When IFN-AD was given as single daily doses (5 X 10(7) units/kg/day X 3 days), the half-life of antipyrine increased by a mean of 40% (from 21.0 to 28.9 min). However, when a smaller daily dose (3 X 10(7) units/kg/day) was given as a continuous infusion, the antipyrine half-life increased by more than 3-fold (from 20.8 to 68.5 min) after 3 days of administration. Continued infusion for a further 3 days produced no additional change in antipyrine half-life. These results demonstrate that human leukocyte interferons can significantly inhibit hepatic metabolic activity in vivo.
Insights
Human leukocyte interferons, specifically IFN-AD, significantly inhibit drug metabolism in mice. The administration method greatly impacts the extent of this inhibition, affecting antipyrine half-life.
Area of Science:
- Pharmacology
- Immunology
- Hepatology
Background:
- Human leukocyte interferons (IFN-A and IFN-AD) are crucial in immune responses.
- Understanding their impact on drug metabolism is vital for clinical applications.
- Previous research has not fully elucidated the effects of different interferon types and administration routes on hepatic function.
Purpose of the Study:
- To investigate the effects of human leukocyte interferons (IFN-A and IFN-AD) on drug-metabolizing capacity in mice.
- To determine if IFN-A or IFN-AD has a greater impact on drug metabolism.
- To assess how different administration regimens of IFN-AD influence its effect on drug metabolism.
Main Methods:
- Drug-metabolizing capacity was assessed by measuring the half-life of antipyrine.
- 14C-antipyrine was administered, and 14CO2 exhalation rates were analyzed.
- IFN-A and IFN-AD were administered to mice at specific dosages and regimens (single daily doses vs. continuous infusion).
Main Results:
- IFN-AD significantly altered antipyrine half-life, indicating changes in drug metabolism.
- IFN-A showed no significant effect on antipyrine half-life.
- Continuous infusion of IFN-AD resulted in a more pronounced increase in antipyrine half-life compared to single daily doses.
- A 3-day continuous infusion of IFN-AD increased antipyrine half-life over threefold, with no further change after an additional 3 days.
Conclusions:
- Human leukocyte interferons, particularly IFN-AD, can significantly inhibit hepatic metabolic activity in vivo.
- The administration regimen plays a critical role in the extent of metabolic inhibition by IFN-AD.
- These findings highlight the potential for interferons to modulate drug metabolism, necessitating careful consideration in therapeutic strategies.